Bitcoin News Today: Propanc's Crypto-Fueled Cancer Push Faces Investor Skepticism, Shares Drop 10.5%

Australia-based Propanc Biopharma has secured up to $100 million in funding from Hexstone Capital, a crypto-focused family office, to establish a digital asset treasury and advance its cancer therapy developmentPropanc Biopharma Secures Up to $100M for Potential Bitcoin Crypto Treasury in Cancer Therapy Push. The private placement includes an initial $1 million investment through convertible preferred stock, with up to $99 million in additional funding over the next yearBiopharma raises $100M for crypto treasury to back cancer treatment. The proceeds will be allocated to building a crypto treasury and accelerating the development of its lead therapy, PRP, which is expected to enter first-in-human trials by the second half of 2026Propanc Biopharma, Inc. Announces Strategic Initiative to Acquire Undervalued Digital Asset Treasury Companies. CEO James Nathanielsz described the move as a "transformative phase" for the company, emphasizing its potential to strengthen Propanc's balance sheet and diversify its asset basePropanc Biopharma plans to acquire digital asset treasury companies.

The funding strategy reflects a growing trend among biotech firms to leverage crypto treasuries amid challenging capital markets. Companies like Sonnet BioTherapeutics and Sharps Technology have similarly adopted digital asset strategies to attract investor interest and diversify funding sourcesPropanc Biopharma Bags $100M Funds to Drive Digital Asset Plans. According to industry analysts, this shift has gained momentum since 2023, as biotech firms seek non-dilutive capital in the $2.5 trillion cryptocurrency marketBiotech firm Propanc lines up $100 million to fund crypto treasury and cancer therapy push. Propanc's approach, however, has faced mixed market reactions.

Shares of Propanc (PPCB) fell 10.5% on Nasdaq following the announcement, extending a 46.7% decline over the past monthPropanc Biopharma Secures Up to $100M for Potential Bitcoin Crypto Treasury in Cancer Therapy Push. The drop underscores investor skepticism toward crypto integrations in traditional sectors, particularly amid recent volatility in Bitcoin and Ethereum pricesBiopharma raises $100M for crypto treasury to back cancer treatment.

Hexstone Capital, which has backed other crypto treasury initiatives, has not disclosed specific digital assets Propanc plans to acquire. However, the firm's portfolio includes Bitcoin (BTC), Ether (ETH), Solana (SOL), and Injective (INJ), indicating potential exposure to high-growth crypto assetsPropanc Biopharma Secures Up to $100M for Potential Bitcoin Crypto Treasury in Cancer Therapy Push. Propanc's CEO highlighted that the proenzyme-based therapy targets not only solid tumor cancers but also chronic diseases, leveraging its unique mechanism of actionPropanc Biopharma, Inc. Announces Strategic Initiative to Acquire Undervalued Digital Asset Treasury Companies. The company aims to mitigate traditional biotech funding challenges by tying capital disbursements to clinical milestones, ensuring funds directly fuel R&D rather than speculative venturesBiotech firm Propanc lines up $100 million to fund crypto treasury and cancer therapy push.

The broader market for crypto treasury companies has faced headwinds, with entities like Strategy and Metaplanet experiencing significant declines in market valueBiopharma raises $100M for crypto treasury to back cancer treatment. Despite these challenges, Propanc's structured funding model-phasely allocating capital to trials and treasury expansion-seeks to balance innovation with fiscal prudenceBiotech firm Propanc lines up $100 million to fund crypto treasury and cancer therapy push. Analysts note that while crypto strategies can accelerate fundraising by 20-30% compared to traditional roundsPropanc Biopharma Secures Up to $100M for Potential Bitcoin Crypto Treasury in Cancer Therapy Push, they also introduce regulatory and volatility risks. The SEC's scrutiny of crypto disclosures further complicates adoption, requiring transparent reporting to avoid misleading investorsBiotech firm Propanc lines up $100 million to fund crypto treasury and cancer therapy push.

Propanc's dual focus on oncology and digital assets positions it at the intersection of two high-growth sectors. Preclinical trials of PRP have shown a 70% reduction in tumor size in animal modelsPropanc Biopharma Secures Up to $100M for Potential Bitcoin Crypto Treasury in Cancer Therapy Push, offering hope for patients with metastatic cancers. As the company progresses toward human trials in 2026, investors will closely watch clinical updates and market stability to gauge the long-term viability of its hybrid strategyPropanc Biopharma, Inc. Announces Strategic Initiative to Acquire Undervalued Digital Asset Treasury Companies.